Clinical implications of interleukins-31, 32, and 33 in gastric cancer

Figure 2 Representative images of immunohistochemical staining for interleukin-31, interleukin-32, and interleukin-33 and their densities in non-cancerous and gastric cancer tissues, as well as their levels in peripheral blood of gastric cancer patients and healthy individuals. A-C: Positive (brown) interleukin (IL)-31 expression in gastric cancer (A) and noncancerous tissues (B) and quantified data (C); D, H, and L: IL-31 (D), IL-32 (H), and IL-33 (L) levels in peripheral blood from gastric cancer (GC) patients and healthy controls (HC); E-G: Positive IL-32 expression in gastric cancer (E) and noncancerous tissues (F) and quantified data (G); I-K: Positive IL-33 expression in gastric cancer (I) and noncancerous tissues (J) and quantified data (K). The densities of IL-31 and IL-33 were all decreased in GC compared to tumour-adjacent normal gastric tissues. Magnification, 600 ×. ^aP < 0.05; ^bP < 0.01; ^cP < 0.0001; ^dP < 0.05. GC: Gastric cancer; IL: Interleukin.